Evidence map›Paper›PMID 39502790›Full record

ArticleAnimal cells and systems2024

AP001885.4 promotes the proliferation of esophageal squamous cell carcinoma cells by histone lactylation- and NF-κB (p65)-dependent transcription activation and METTL3-mediated mRNA stability of c-myc.

Chuang Fu, Wen Jiang, Chong Wang, Sheng-Jie Song, Hao Tao, Xin-Guo Zhang, Wen-Ting Li, Xin Jin, Bin-Bing Yu, Jia-Jie Hao and 3 more

Abstract read
In one paragraph

Article in Animal cells and systems, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Review
  2. Research progress of lactylation modification in tumors (Review).Experimental and therapeutic medicine · 2026
    Review
  3. Lactylation Modification and Esophageal Cancer: Research Progress From Hypoxia-Induced Metabolic Reprogramming to Immune Escape.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Review
  4. Review
  5. Review
  6. Role of histone modifications in gastric cancer (Review).International journal of oncology · 2026
    Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Chuang FuMedical School, Kunming University of Science and Technology, Kunming, People's Republic of China.
Wen JiangDepartment of Thoracic Surgery, the Affiliated Hospital of Kunming University of Science and Technology and First People's Hospital of Yunnan Province, Kunming, People's Republic of China.
Chong WangMedical School, Kunming University of Science and Technology, Kunming, People's Republic of China.
Sheng-Jie SongMedical School, Kunming University of Science and Technology, Kunming, People's Republic of China.
Hao TaoMedical School, Kunming University of Science and Technology, Kunming, People's Republic of China.
Xin-Guo ZhangMedical School, Kunming University of Science and Technology, Kunming, People's Republic of China.
Wen-Ting LiMedical School, Kunming University of Science and Technology, Kunming, People's Republic of China.
Xin JinMedical School, Kunming University of Science and Technology, Kunming, People's Republic of China.
Bin-Bing YuDepartment of Anus & Intestine Surgery, Kunming Municipal Hospital of Traditional Chinese Medicine, Kunming, People's Republic of China.
Jia-Jie HaoState Key Laboratory of Molecular Oncology, Center for Cancer Precision Medicine, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College (PUMC), Beijing, People's Republic of China.
Wen-Juan SunNephrology Division, Pu'er People's Hospital, Pu'er, People's Republic of China.
Jie BaiMedical School, Kunming University of Science and Technology, Kunming, People's Republic of China.
Zhi-Zhou ShiMedical School, Kunming University of Science and Technology, Kunming, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Esophageal squamous cell carcinoma (ESCC) is an aggressive malignant neoplasm, and up to now, the role of long non-coding RNA (lncRNA) AP001885.4 in cancer, including ESCC, is absolutely unclear. The GEPIA database was applied to identify differentially expressed and prognosis-associated genes in esophageal cancer (ESCA). CCK-8, colony formation, Western blot, and qRT-PCR methods were harnessed to investigate the role and mechanism of AP001885.4 in esophageal carcinogenesis. By analyzing TCGA data in the GEPIA database, two lncRNAs were selected. AP001885.4 was overexpressed and positively associated with the unfavorable outcome of ESCC patients, and LINC001786 was under-expressed and negatively linked with the poor prognosis. Knockdown of AP001885.4 suppressed the proliferation and colony formation of ESCC cells. Importantly, the silence of AP001885.4 downregulated c-myc. Mechanically, the knockdown of AP001885.4 reduced METTL3 expression and m6A modification in c-myc mRNA, and METTL3 positively regulated c-myc. Furthermore, the knockdown of AP001885.4 diminished histone lactylation and NF-κB (p65) expression, and the protein lactylation inhibitors (2-DG, 2-deoxy-D-glucose and oxamate) and the NF-κB inhibitor (JSH-23) also lessened c-myc expression. Consequently, our findings suggested that AP001885.4 promoted the proliferation of esophageal squamous cell carcinoma cells by histone lactylation- and NF-κB (p65)-dependent transcription activation and METTL3-mediated mRNA stability of c-myc.

Indexed as

AP001885.4C-mycESCClactylationNF-κB

Identifiers

PMID39502790
PMCPMC11536669

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.